[A phase II study of 590-S (1-phthalidyl-5-fluorouracil) in patients with breast cancer--multi-center cooperative study--Cooperative Study Group of 590-S in Breast Cancer].
A phase II clinical study involving 16 institutions was performed for the treatment of breast cancer with 590-S, a new masked fluoropyrimidine derivative. A dose of 900 mg/day was administered orally for more than 4 weeks. Out of 33 cases enrolled, 18 were completely recorded and evaluable. The response rate was 33.3%: 2 CR and 4 PR. It was noteworthy that, out of 12 cases previously treated with other 5-FU derivatives, 5 cases (41.7%) were judged as effective. Of 26 cases, side effects were observed in 8 (30.8%). All of these were gastrointestinal disorders such as nausea, vomiting, and loss of appetite. 590-S is considered to be a useful antitumor agent. However, further investigation will be required.